ArticleScientific reports2025
FeBTC as peroxidase mimic for colorimetric cholesterol detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cholesterol sensing is essential for the early detection of several diseases such as hypercholesterolemia, atherosclerosis, and cardiovascular disorders. To address the limitations of enzyme-based methods, this paper proposes a novel Metal Organic Framework (MOF)-based spectrophotometric platform for cholesterol detection. Iron-based MOF (Fe-BTC) is introduced as a novel, peroxidase mimic nanozyme for cholesterol detection. Characterization studies run on Fe-BTC, including Fourier transform infrared spectroscopy, X-ray diffraction, and zeta potential, revealed its stable, amorphous nature and potential peroxidase activity due to Fe centers. Parametric studies including pH, time, temperature, and reagent concentrations were performed to determine operating conditions for H2O2 and cholesterol detection. Mechanistic studies demonstrated biosensor operation via OH· radical formation by Fe-BTC. The present biosensor achieved a cholesterol limit of detection (LOD) of 2.91 µM and 2.88 µM at 25 °C and 37 °C cholesterol incubation, respectively, with a linear detection range of 6.56–78.75 µM at both temperatures. The biosensor had good selectivity to cholesterol in the presence of interfering analytes, including glycine, uric acid, glucose, and NaCl. Overall, our novel Fe-BTC-based biosensor demonstrated comparable performance to nanomaterial-based cholesterol sensors reported in the literature, with a simpler, cheaper, and scalable design, and shows great promise for cholesterol detection via spectrophotometric methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.